CCMG
SCMP

Clark Capital Management Group’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Clark Capital Management Group’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-90,101
Closed -$991K – 325
2017
Q1 		$991K Buy
90,101
+31,057
+53% +$360K 0.04% 204
2016
Q4 		$800K Buy
+59,044
New +$824K 0.04% 216

Other funds holding SCMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Clark Capital Management Group's SCMP Position: Q2 2017 in Review

Clark Capital Management Group sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q2 2017, closing a stake of 90,101 shares — an estimated $991K sold.

Clark Capital Management Group first reported a position in SCMP in Q4 2016 and held it in 2 quarters. The position peaked at $991K in Q1 2017. 167 funds tracked by Wall St. Rank hold SCMP as of Q2 2017.

  • Clark Capital Management Group reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Clark Capital Management Group sold 90,101 Sucampo Pharmaceuticals, Inc. shares in Q2 2017, an estimated $991K.
  • Clark Capital Management Group first reported a position in Sucampo Pharmaceuticals, Inc. in Q4 2016 and held it in 2 quarters.
  • Clark Capital Management Group's Sucampo Pharmaceuticals, Inc. position peaked at $991K in Q1 2017.
  • 167 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q2 2017.

Based on Clark Capital Management Group's 13F filing for Q2 2017, filed 14 Aug 2017.